Search clinical trials for: AG011

Total 5 results

ActoGeniX N.V.

Completed

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

Moderately Active Ulcerative Colitis

Canada, Netherlands, Sweden, Belgium
Precigen Actobio T1D, LLC
TFS Trial Form Support; Intrexon Actobiotics NV, d/b/a Precigen Actobio

Completed

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

Diabetes Mellitus, Type 1

United States, Belgium
ActoGeniX N.V.

Completed

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

Oral Mucositis

United States
Oragenics, Inc.

Terminated

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

Oral Mucositis

United Kingdom, United States, Belgium, Germany
CARsgen Therapeutics Co., Ltd.
Shanghai East Hospital

Active, not recruiting

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor

China

3

Subscribe